In agreement with several previous studies establishing a prognostic value for VEGF-A in breast cancer [30,31], a high VEGF-A expression was associated with poor RFS in all patients (n = 3951), ER-patients (n = 801), PR- patients (n = 549), patients with HER2- status (n = 800), triple-negative patients (n = 255), and patients with grade II tumors (n = 901) (Supplementary Table S3). Here, ESR1 is linked to breast cancer.